Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial
Treatment regimen an iwCLL and MRD response.
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2024-06, Vol.99 (6), p.1192-1195 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1195 |
|---|---|
| container_issue | 6 |
| container_start_page | 1192 |
| container_title | American journal of hematology |
| container_volume | 99 |
| creator | Cramer, Paula Tresckow, Julia Fink, Anna‐Maria Robrecht, Sandra Giza, Adam Tausch, Eugen Müller, Lothar Knauf, Wolfgang Zingerle, Matthias Al‐Sawaf, Othman Langerbeins, Petra Fischer, Kirsten Kreuzer, Karl‐Anton Kneba, Michael Wendtner, Clemens‐Martin Stilgenbauer, Stephan Eichhorst, Barbara Hallek, Michael |
| description | Treatment regimen an iwCLL and MRD response. |
| doi_str_mv | 10.1002/ajh.27304 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3034248206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3054810513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3484-a7d5b335df3439c5b6bbc972bce0a3d28bbc2c0f6edf2b9c3f4ea8af03baa6f03</originalsourceid><addsrcrecordid>eNp1kctq3DAUhkVpaSZpFn2BIugmgUwiS7bHzi4Zcpky0E2zNkfyMaOpLLmSRXBXfYQ8RJ-sTxJNJ-2i0M25wHc-OPyEvM_YecYYv4Dt5pwvBMtfkVnG6nJelQV_TWZMlFmaWX1ADkPYMpZlecXekgNRFYuKcT4jP6_RttDHMGqLZ7RzxrhHbKmcqJPaxjF-jz1ICralukUDRgctqbZUbbyzWlEz9cPGqWnczRi_Yq-BnizXa_7rx9P18u70kt5qCyYpwExBB-o6CrSPJl2gHdGfUTegTbQBiYYOGwiYttUqldFrMO_Imw5MwOOXfkQebm--LO_n6893q-XVeq5EXuVzWLSFFKJoO5GLWhWylFLVCy4VMhAtr9LKFetKbDsuayW6HKGCjgkJUKZ2RE723sG7bxHD2PQ6KDQGLLoYGsFEzvOKszKhH_9Bty769OGOKvIqY0UmEnW6p5R3IXjsmsHrHvzUZKzZRdek6Jrf0SX2w4sxyh7bv-SfrBJwsQcetcHp_6bm6tP9XvkMvYao5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3054810513</pqid></control><display><type>article</type><title>Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Cramer, Paula ; Tresckow, Julia ; Fink, Anna‐Maria ; Robrecht, Sandra ; Giza, Adam ; Tausch, Eugen ; Müller, Lothar ; Knauf, Wolfgang ; Zingerle, Matthias ; Al‐Sawaf, Othman ; Langerbeins, Petra ; Fischer, Kirsten ; Kreuzer, Karl‐Anton ; Kneba, Michael ; Wendtner, Clemens‐Martin ; Stilgenbauer, Stephan ; Eichhorst, Barbara ; Hallek, Michael</creator><creatorcontrib>Cramer, Paula ; Tresckow, Julia ; Fink, Anna‐Maria ; Robrecht, Sandra ; Giza, Adam ; Tausch, Eugen ; Müller, Lothar ; Knauf, Wolfgang ; Zingerle, Matthias ; Al‐Sawaf, Othman ; Langerbeins, Petra ; Fischer, Kirsten ; Kreuzer, Karl‐Anton ; Kneba, Michael ; Wendtner, Clemens‐Martin ; Stilgenbauer, Stephan ; Eichhorst, Barbara ; Hallek, Michael</creatorcontrib><description>Treatment regimen an iwCLL and MRD response.</description><identifier>ISSN: 0361-8609</identifier><identifier>ISSN: 1096-8652</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.27304</identifier><identifier>PMID: 38578022</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bendamustine Hydrochloride - administration & dosage ; Bendamustine Hydrochloride - therapeutic use ; Chronic lymphocytic leukemia ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Lymphatic leukemia ; Male ; Middle Aged ; Purines - administration & dosage ; Purines - adverse effects ; Purines - therapeutic use ; Quinazolinones - administration & dosage ; Quinazolinones - adverse effects ; Quinazolinones - therapeutic use</subject><ispartof>American journal of hematology, 2024-06, Vol.99 (6), p.1192-1195</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3484-a7d5b335df3439c5b6bbc972bce0a3d28bbc2c0f6edf2b9c3f4ea8af03baa6f03</cites><orcidid>0000-0003-4046-9922 ; 0000-0001-9895-0570 ; 0000-0002-6654-0304</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.27304$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.27304$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38578022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cramer, Paula</creatorcontrib><creatorcontrib>Tresckow, Julia</creatorcontrib><creatorcontrib>Fink, Anna‐Maria</creatorcontrib><creatorcontrib>Robrecht, Sandra</creatorcontrib><creatorcontrib>Giza, Adam</creatorcontrib><creatorcontrib>Tausch, Eugen</creatorcontrib><creatorcontrib>Müller, Lothar</creatorcontrib><creatorcontrib>Knauf, Wolfgang</creatorcontrib><creatorcontrib>Zingerle, Matthias</creatorcontrib><creatorcontrib>Al‐Sawaf, Othman</creatorcontrib><creatorcontrib>Langerbeins, Petra</creatorcontrib><creatorcontrib>Fischer, Kirsten</creatorcontrib><creatorcontrib>Kreuzer, Karl‐Anton</creatorcontrib><creatorcontrib>Kneba, Michael</creatorcontrib><creatorcontrib>Wendtner, Clemens‐Martin</creatorcontrib><creatorcontrib>Stilgenbauer, Stephan</creatorcontrib><creatorcontrib>Eichhorst, Barbara</creatorcontrib><creatorcontrib>Hallek, Michael</creatorcontrib><title>Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Treatment regimen an iwCLL and MRD response.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bendamustine Hydrochloride - administration & dosage</subject><subject>Bendamustine Hydrochloride - therapeutic use</subject><subject>Chronic lymphocytic leukemia</subject><subject>Female</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Purines - administration & dosage</subject><subject>Purines - adverse effects</subject><subject>Purines - therapeutic use</subject><subject>Quinazolinones - administration & dosage</subject><subject>Quinazolinones - adverse effects</subject><subject>Quinazolinones - therapeutic use</subject><issn>0361-8609</issn><issn>1096-8652</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctq3DAUhkVpaSZpFn2BIugmgUwiS7bHzi4Zcpky0E2zNkfyMaOpLLmSRXBXfYQ8RJ-sTxJNJ-2i0M25wHc-OPyEvM_YecYYv4Dt5pwvBMtfkVnG6nJelQV_TWZMlFmaWX1ADkPYMpZlecXekgNRFYuKcT4jP6_RttDHMGqLZ7RzxrhHbKmcqJPaxjF-jz1ICralukUDRgctqbZUbbyzWlEz9cPGqWnczRi_Yq-BnizXa_7rx9P18u70kt5qCyYpwExBB-o6CrSPJl2gHdGfUTegTbQBiYYOGwiYttUqldFrMO_Imw5MwOOXfkQebm--LO_n6893q-XVeq5EXuVzWLSFFKJoO5GLWhWylFLVCy4VMhAtr9LKFetKbDsuayW6HKGCjgkJUKZ2RE723sG7bxHD2PQ6KDQGLLoYGsFEzvOKszKhH_9Bty769OGOKvIqY0UmEnW6p5R3IXjsmsHrHvzUZKzZRdek6Jrf0SX2w4sxyh7bv-SfrBJwsQcetcHp_6bm6tP9XvkMvYao5g</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Cramer, Paula</creator><creator>Tresckow, Julia</creator><creator>Fink, Anna‐Maria</creator><creator>Robrecht, Sandra</creator><creator>Giza, Adam</creator><creator>Tausch, Eugen</creator><creator>Müller, Lothar</creator><creator>Knauf, Wolfgang</creator><creator>Zingerle, Matthias</creator><creator>Al‐Sawaf, Othman</creator><creator>Langerbeins, Petra</creator><creator>Fischer, Kirsten</creator><creator>Kreuzer, Karl‐Anton</creator><creator>Kneba, Michael</creator><creator>Wendtner, Clemens‐Martin</creator><creator>Stilgenbauer, Stephan</creator><creator>Eichhorst, Barbara</creator><creator>Hallek, Michael</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4046-9922</orcidid><orcidid>https://orcid.org/0000-0001-9895-0570</orcidid><orcidid>https://orcid.org/0000-0002-6654-0304</orcidid></search><sort><creationdate>202406</creationdate><title>Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial</title><author>Cramer, Paula ; Tresckow, Julia ; Fink, Anna‐Maria ; Robrecht, Sandra ; Giza, Adam ; Tausch, Eugen ; Müller, Lothar ; Knauf, Wolfgang ; Zingerle, Matthias ; Al‐Sawaf, Othman ; Langerbeins, Petra ; Fischer, Kirsten ; Kreuzer, Karl‐Anton ; Kneba, Michael ; Wendtner, Clemens‐Martin ; Stilgenbauer, Stephan ; Eichhorst, Barbara ; Hallek, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3484-a7d5b335df3439c5b6bbc972bce0a3d28bbc2c0f6edf2b9c3f4ea8af03baa6f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bendamustine Hydrochloride - administration & dosage</topic><topic>Bendamustine Hydrochloride - therapeutic use</topic><topic>Chronic lymphocytic leukemia</topic><topic>Female</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Purines - administration & dosage</topic><topic>Purines - adverse effects</topic><topic>Purines - therapeutic use</topic><topic>Quinazolinones - administration & dosage</topic><topic>Quinazolinones - adverse effects</topic><topic>Quinazolinones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cramer, Paula</creatorcontrib><creatorcontrib>Tresckow, Julia</creatorcontrib><creatorcontrib>Fink, Anna‐Maria</creatorcontrib><creatorcontrib>Robrecht, Sandra</creatorcontrib><creatorcontrib>Giza, Adam</creatorcontrib><creatorcontrib>Tausch, Eugen</creatorcontrib><creatorcontrib>Müller, Lothar</creatorcontrib><creatorcontrib>Knauf, Wolfgang</creatorcontrib><creatorcontrib>Zingerle, Matthias</creatorcontrib><creatorcontrib>Al‐Sawaf, Othman</creatorcontrib><creatorcontrib>Langerbeins, Petra</creatorcontrib><creatorcontrib>Fischer, Kirsten</creatorcontrib><creatorcontrib>Kreuzer, Karl‐Anton</creatorcontrib><creatorcontrib>Kneba, Michael</creatorcontrib><creatorcontrib>Wendtner, Clemens‐Martin</creatorcontrib><creatorcontrib>Stilgenbauer, Stephan</creatorcontrib><creatorcontrib>Eichhorst, Barbara</creatorcontrib><creatorcontrib>Hallek, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cramer, Paula</au><au>Tresckow, Julia</au><au>Fink, Anna‐Maria</au><au>Robrecht, Sandra</au><au>Giza, Adam</au><au>Tausch, Eugen</au><au>Müller, Lothar</au><au>Knauf, Wolfgang</au><au>Zingerle, Matthias</au><au>Al‐Sawaf, Othman</au><au>Langerbeins, Petra</au><au>Fischer, Kirsten</au><au>Kreuzer, Karl‐Anton</au><au>Kneba, Michael</au><au>Wendtner, Clemens‐Martin</au><au>Stilgenbauer, Stephan</au><au>Eichhorst, Barbara</au><au>Hallek, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2024-06</date><risdate>2024</risdate><volume>99</volume><issue>6</issue><spage>1192</spage><epage>1195</epage><pages>1192-1195</pages><issn>0361-8609</issn><issn>1096-8652</issn><eissn>1096-8652</eissn><abstract>Treatment regimen an iwCLL and MRD response.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>38578022</pmid><doi>10.1002/ajh.27304</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4046-9922</orcidid><orcidid>https://orcid.org/0000-0001-9895-0570</orcidid><orcidid>https://orcid.org/0000-0002-6654-0304</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2024-06, Vol.99 (6), p.1192-1195 |
| issn | 0361-8609 1096-8652 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3034248206 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - administration & dosage Bendamustine Hydrochloride - therapeutic use Chronic lymphocytic leukemia Female Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphatic leukemia Male Middle Aged Purines - administration & dosage Purines - adverse effects Purines - therapeutic use Quinazolinones - administration & dosage Quinazolinones - adverse effects Quinazolinones - therapeutic use |
| title | Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T18%3A06%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bendamustine,%20followed%20by%20obinutuzumab%20and%20idelalisib%20in%20chronic%20lymphocytic%20leukemia%20(CLL2%E2%80%90BCG):%20Final%20analysis%20of%20a%20multicenter,%20open%E2%80%90label%20phase%E2%80%90II%E2%80%90trial&rft.jtitle=American%20journal%20of%20hematology&rft.au=Cramer,%20Paula&rft.date=2024-06&rft.volume=99&rft.issue=6&rft.spage=1192&rft.epage=1195&rft.pages=1192-1195&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.27304&rft_dat=%3Cproquest_cross%3E3054810513%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3054810513&rft_id=info:pmid/38578022&rfr_iscdi=true |